Ceclor®
Cefaclor · oral capsule
Antibiotic
Approved uses
Otitis media, lower respiratory tract infection, pharyngitis and tonsillitis, urinary tract infection, and skin and skin structure infections due to susceptible organisms
Adults: 250 mg PO q8h; doses may be doubled for more severe infections or less susceptible organisms. Children: 20 mg/kg/day PO divided q8h, or 40 mg/kg/day for otitis media, more serious infections, and less susceptible organisms, maximum 1 g/day. At least 10 days for beta-hemolytic streptococcal infection
Contraindications
Known allergy to the cephalosporin group of antibiotics.
250 mg and 500 mg capsules, each in bottles of 30, 100, and 500
Bactericidal by inhibition of bacterial cell wall synthesis, as with other cephalosporins. Pseudomonas spp., Acinetobacter calcoaceticus, most strains of enterococci, Enterobacter spp., indole-positive Proteus, Morganella morganii, Providencia rettgeri, and Serratia spp. are resistant. Cefaclor is inactive against methicillin-resistant staphylococci, and beta-lactamase-negative ampicillin-resistant Haemophilus influenzae should be treated as resistant despite apparent in vitro susceptibility.
Warnings & Precautions
- Cross-hypersensitivity: Before therapy, ask whether the patient has had previous hypersensitivity reactions to cefaclor, cephalosporins, penicillins, or other drugs. Use caution in penicillin-sensitive patients, because cross-hypersensitivity among beta-lactam antibiotics has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. Give antibiotics cautiously to any patient who has shown some form of allergy, particularly to drugs.
- Serious acute hypersensitivity reactions: If an allergic reaction to cefaclor occurs, discontinue the drug. Serious acute hypersensitivity reactions may require epinephrine and other emergency measures, including oxygen, IV fluids, IV antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated.
- Methicillin-resistant staphylococci: Cefaclor is inactive against methicillin-resistant staphylococci.
- BLNAR Haemophilus influenzae: Beta-lactamase-negative ampicillin-resistant strains should be considered resistant despite apparent in vitro susceptibility.
- Pseudomembranous colitis: Reported with nearly all antibacterials, mild to life-threatening; consider it in any diarrhea during or after therapy. Mild cases usually respond to drug discontinuation alone. In moderate to severe cases, consider fluids and electrolytes, protein supplementation, and an antibacterial drug effective against C. difficile.
- Gastrointestinal history: Caution in patients with a history of gastrointestinal disease, particularly colitis.
- Positive Coombs test: Reported during cephalosporin therapy and may confound transfusion cross-matching and Coombs testing of newborns.
- Renal impairment: Caution with markedly impaired function; dosage adjustment is usually not required, since the half-life in anuria is 2.3 to 2.8 hours. Clinical experience in this setting is limited, so careful clinical observation and laboratory studies should be made.
- Seizures: Several cephalosporins have been implicated in triggering seizures, particularly in renal impairment when the dose was not reduced. If seizures associated with drug therapy occur, discontinue the drug; anticonvulsant therapy can be given if clinically indicated.
- Superinfection: Prolonged use may result in overgrowth of nonsusceptible organisms. If superinfection occurs during therapy, take appropriate measures.
- Increased anticoagulant effect: Increased anticoagulant effect has been reported when cefaclor and oral anticoagulants were given together.
- Inhibited renal excretion: As with other beta-lactam antibiotics, probenecid inhibits the renal excretion of cefaclor.
- False-positive urine glucose: Patients receiving cefaclor may show a false-positive reaction for glucose in the urine with Benedict's and Fehling's solutions and with Clinitest tablets.
- Drug-resistant bacteria: Prescribing cefaclor without a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit and increases the risk of drug-resistant bacteria.
Common Side Effects
Hypersensitivity reactions have been reported in about 1.5%, including morbilliform eruptions (1 in 100); pruritus, urticaria, and positive Coombs tests each occur in under 1 in 200. Serum-sickness-like reactions occur in 0.024% in overall clinical trials and 0.5% in one focused trial; they occur more often during or after a second (or subsequent) course and are reported more often in pediatric patients. Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely; anaphylaxis may be more common with a history of penicillin allergy. Gastrointestinal symptoms occur in about 2.5%, including diarrhea (1 in 70); nausea, vomiting, transient hepatitis, and cholestatic jaundice are reported rarely. Eosinophilia occurs in 1 in 50 and genital pruritus, moniliasis, or vaginitis in about 1 in 50; thrombocytopenia and reversible interstitial nephritis are rare.
Pregnancy: Category B. No fetal harm in mice and rats at up to 12 times the human dose or in ferrets at 3 times the maximum human dose; no adequate and well-controlled studies in pregnant women, so use only if clearly needed.
Lactation: Small amounts appear in milk, averaging 0.16 to 0.21 mcg/mL between 2 and 5 hours after a single 500 mg dose; the effect on the nursing infant is unknown. Use caution when cefaclor is given to a nursing woman.
Safety and effectiveness not established under 1 month of age.